Incidence, clinical predictors, and clinical effect of new-onset atrial fibrillation in myocardial infarction patients

References

1. 1.↵
   1. Schmitt J,
   2. Duray G,
   3. Gersh BJ,
   4. Hohnloser SH

   . Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30: 1038–1045.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Kundu A,
   2. O’Day K,
   3. Shaikh AY,
   4. Lessard DM,
   5. Saczynski JS,
   6. Yarzebski J, et al.

   Relation of atrial fibrillation in acute myocardial infarction to in-hospital complications and early hospital readmission. Am J Cardiol 2016; 117: 1213–1218.

   OpenUrl
3. 3.↵
   1. Jabre P,
   2. Roger VL,
   3. Murad MH,
   4. Chamberlain AM,
   5. Prokop L,
   6. Adnet F, et al.

   Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation 2011; 123: 1587–1593.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Rhyou HI,
   2. Park TH,
   3. Cho YR,
   4. Park K,
   5. Park JS,
   6. Kim MH, et al.

   Clinical factors associated with the development of atrial fibrillation in the year following STEMI treated by primary PCI. J Cardiol 2018; 71: 125–128.

   OpenUrl
5. 5.↵
   1. Parashar S,
   2. Kella D,
   3. Reid KJ,
   4. Spertus JA,
   5. Tang F,
   6. Langberg J, et al.

   New-onset atrial fibrillation after acute myocardial infarction and its relation to admission biomarkers (from the TRIUMPH registry). Am J Cardiol 2013; 112: 1390–1395.

   OpenUrlCrossRefPubMed
6. 6.
   1. Iqbal Z,
   2. Mengal MN,
   3. Badini A,
   4. Karim M

   . New-onset atrial fibrillation in patients presenting with acute myocardial infarction. Cureus 2019; 11: e4483.

   OpenUrl
7. 7.↵
   1. Congo KH,
   2. Belo A,
   3. Carvalho J,
   4. Neves D,
   5. Guerreiro R,
   6. Pais JA, et al.

   New-onset atrial fibrillation in ST-segment elevation myocardial infarction: predictors and impact on therapy and mortality. Arq Bras Cardiol 2019; 113: 948–957.

   OpenUrl
8. 8.↵
   1. He J,
   2. Yang Y,
   3. Zhang G,
   4. Lu XH

   . Clinical risk factors for new-onset atrial fibrillation in acute myocardial infarction: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e15960.

   OpenUrl
9. 9.↵
   1. Ogunsua A,
   2. Vaze A,
   3. Kassas I,
   4. Hansra B,
   5. Nagy A,
   6. Elhag R, et al.

   TCT-150 risk factors for new-onset atrial fibrillation after percutaneous coronary intervention among patients with non-ST elevation myocardial infarction. J Am Coll Cardiol 2017; 70: B65.

   OpenUrlCrossRef
10. 10.↵
    1. Von Elm E,
    2. Altman DG,
    3. Egger M,
    4. Pocock SJ,
    5. Gøtzsche PC,
    6. Vandenbroucke JP

    . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Go AS,
    2. Hylek EM,
    3. Phillips KA,
    4. Chang Y,
    5. Henault LE,
    6. Selby JV, et al.

    Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–2375.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Carro A,
    2. Kaski JC

    . Myocardial infarction in the elderly. Aging Dis 2011; 2: 116–137.

    OpenUrlPubMed
13. 13.↵
    1. Motivala AA,
    2. Tamhane U,
    3. Ramanath VS,
    4. Saab F,
    5. Montgomery DG,
    6. Fang J, et al.

    A prior myocardial infarction: how does it affect management and outcomes in recurrent acute coronary syndromes? Clin Cardiol 2008; 31: 590–596.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Durak-Nalbantić A,
    2. Džubur A,
    3. Dilić M,
    4. Pozderac Z,
    5. Mujanović-Narančić A,
    6. Kulić M, et al.

    Brain natriuretic peptide release in acute myocardial infarction. Bosn J Basic Med Sci 2012; 12: 164–168.

    OpenUrlPubMed
15. 15.↵
    1. Lloyd-Jones DM,
    2. Wang TJ,
    3. Leip EP,
    4. Larson MG,
    5. Levy D,
    6. Vasan RS, et al.

    Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110: 1042–1046.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Patton KK,
    2. Ellinor PT,
    3. Heckbert SR,
    4. Christenson RH,
    5. DeFilippi C,
    6. Gottdiener JS, et al.

    N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the cardiovascular health study. Circulation 2009; 120: 1768–1774.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Ergün B,
    2. Ergan B,
    3. Sözmen MK,
    4. Küçük M,
    5. Yakar MN,
    6. Cömert B, et al.

    New-onset atrial fibrillation in critically ill patients with coronavirus disease 2019 (COVID-19). J Arrhythm 2021; 37: 1196–1204.

    OpenUrl
18. 18.↵
    1. Walker HK,
    2. Hall WD,
    3. Hurst JW

    1. Hosten AO

    . BUN and creatinine. In: Walker HK, Hall WD, Hurst JW, editors. Clinical methods: the history, physical, and laboratory examinations (3rd ed). Butterworths 1990: Chapter 193.
19. 19.↵
    1. McManus DD,
    2. Huang W,
    3. Domakonda KV,
    4. Ward J,
    5. Saczysnki JS,
    6. Gore JM, et al.

    Trends in atrial fibrillation in patients hospitalized with an acute coronary syndrome. Am J Med 2012; 125: 1076–1084.

    OpenUrlPubMed
20. 20.↵
    1. Alkhouli M,
    2. Alqahtani F,
    3. Kalra A,
    4. Gafoor S,
    5. Alhajji M,
    6. Alreshidan M, et al.

    Trends in characteristics and outcomes of patients undergoing coronary revascularization in the United States, 2003-2016. JAMA Netw Open 2020; 3: e1921326.